Valby, Denmark, February 22, 2020 – H. Lundbeck A/S today announced that Vyepti (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults and will be available in…Original Article
FDA Approves Vyepti (eptinezumab-jjmr) Intravenous Injection for the Preventive Treatment of Migraine
